CN111254146A - Application of LINC01331 gene inhibitor in preparation of medicine for treating lung cancer - Google Patents
Application of LINC01331 gene inhibitor in preparation of medicine for treating lung cancer Download PDFInfo
- Publication number
- CN111254146A CN111254146A CN202010174969.6A CN202010174969A CN111254146A CN 111254146 A CN111254146 A CN 111254146A CN 202010174969 A CN202010174969 A CN 202010174969A CN 111254146 A CN111254146 A CN 111254146A
- Authority
- CN
- China
- Prior art keywords
- linc01331
- lung cancer
- gene inhibitor
- sirna
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010058467 Lung neoplasm malignant Diseases 0.000 title claims abstract description 46
- 201000005202 lung cancer Diseases 0.000 title claims abstract description 44
- 208000020816 lung neoplasm Diseases 0.000 title claims abstract description 44
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 43
- 239000003112 inhibitor Substances 0.000 title claims abstract description 26
- 239000003814 drug Substances 0.000 title claims abstract description 15
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 230000009471 action Effects 0.000 claims abstract description 5
- 108020004459 Small interfering RNA Proteins 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 12
- 230000000694 effects Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 108091081021 Sense strand Proteins 0.000 claims description 7
- 230000000692 anti-sense effect Effects 0.000 claims description 7
- 108091046869 Telomeric non-coding RNA Proteins 0.000 claims description 5
- 108091027963 non-coding RNA Proteins 0.000 claims description 5
- 102000042567 non-coding RNA Human genes 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 150000007523 nucleic acids Chemical group 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims 1
- 230000012292 cell migration Effects 0.000 abstract description 4
- 230000004709 cell invasion Effects 0.000 abstract description 3
- 238000011161 development Methods 0.000 abstract description 3
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 230000009702 cancer cell proliferation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 33
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 18
- 239000007788 liquid Substances 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 201000005249 lung adenocarcinoma Diseases 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 241000282414 Homo sapiens Species 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 239000002033 PVDF binder Substances 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000012679 serum free medium Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108010058546 Cyclin D1 Proteins 0.000 description 3
- 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 3
- 238000002123 RNA extraction Methods 0.000 description 3
- 238000005336 cracking Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000005012 migration Effects 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010068155 Cyclin C Proteins 0.000 description 1
- 102100024170 Cyclin-C Human genes 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000012578 cell culture reagent Substances 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000009546 lung large cell carcinoma Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
sample numbering | Tumor type | Age diagnosis | Sex | M stages | N stages | |
1 | Adenocarcinoma of lung | 67 | For male | M0 | N0 | |
2 | Adenocarcinoma of lung | 78 | Woman | M0 | N1 | |
3 | Adenocarcinoma of lung | 65 | For male | M0 | N0 | |
4 | Adenocarcinoma of lung | 70 | For male | M0 | N2 | |
5 | Adenocarcinoma of lung | 58 | For male | M0 | N0 | |
6 | Adenocarcinoma of lung | 75 | Woman | M0 | N2 | |
7 | Adenocarcinoma of lung | 66 | For | M0 | N1 | |
8 | Adenocarcinoma of lung | 76 | Woman | M0 | N0 | |
9 | Adenocarcinoma of |
48 | Woman | M0 | N3 | |
10 | Adenocarcinoma of lung | 74 | Woman | M0 | N0 | |
11 | Adenocarcinoma of lung | 60 | For male | M0 | N0 | |
12 | Adenocarcinoma of lung | 51 | Woman | M0 | N0 | |
13 | Adenocarcinoma of lung | 57 | For male | M0 | N2 | |
14 | Adenocarcinoma of lung | 68 | For male | M0 | N2 | |
15 | Adenocarcinoma of lung | 40 | For male | M0 | N0 | |
16 | Adenocarcinoma of lung | 43 | For male | M0 | N0 | |
17 | Adenocarcinoma of |
72 | For male | M0 | N1 | |
18 | Adenocarcinoma of lung | 59 | Woman | M0 | N0 | |
19 | Adenocarcinoma of lung | 83 | For male | M0 | N0 | |
20 | Adenocarcinoma of lung | 50 | For male | M0 | N2 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010174969.6A CN111254146B (en) | 2020-03-13 | 2020-03-13 | Application of LINC01331 gene inhibitor in preparation of medicine for treating lung cancer |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010174969.6A CN111254146B (en) | 2020-03-13 | 2020-03-13 | Application of LINC01331 gene inhibitor in preparation of medicine for treating lung cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111254146A true CN111254146A (en) | 2020-06-09 |
CN111254146B CN111254146B (en) | 2021-10-26 |
Family
ID=70949827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010174969.6A Expired - Fee Related CN111254146B (en) | 2020-03-13 | 2020-03-13 | Application of LINC01331 gene inhibitor in preparation of medicine for treating lung cancer |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111254146B (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111743912A (en) * | 2020-07-14 | 2020-10-09 | 济南帕斯维德生物科技有限公司 | Gene inhibitor for promoting colon cancer cell apoptosis and inhibiting colon cancer cell migration |
CN112301032A (en) * | 2020-11-12 | 2021-02-02 | 济南生发堂生物科技股份有限公司 | Gene inhibitor for inhibiting hair follicle stem cell aging |
CN115025216A (en) * | 2022-05-10 | 2022-09-09 | 广州乐康生物医药科技有限公司 | Compositions and methods for cancer therapy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107190005A (en) * | 2017-01-25 | 2017-09-22 | 河北医科大学第四医院(河北省肿瘤医院) | Applications of the lncRNA as biomarker in adenocarcinoma of lung diagnosis and treatment |
-
2020
- 2020-03-13 CN CN202010174969.6A patent/CN111254146B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107190005A (en) * | 2017-01-25 | 2017-09-22 | 河北医科大学第四医院(河北省肿瘤医院) | Applications of the lncRNA as biomarker in adenocarcinoma of lung diagnosis and treatment |
Non-Patent Citations (2)
Title |
---|
HYUNHEE DO等: "Roles of Oncogenic Long Non-coding RNAs in Cancer Development", 《GENOMICS AND INFORMATICS》 * |
KIMURA K等: "NR_126354.1", 《GENBANK》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111743912A (en) * | 2020-07-14 | 2020-10-09 | 济南帕斯维德生物科技有限公司 | Gene inhibitor for promoting colon cancer cell apoptosis and inhibiting colon cancer cell migration |
CN112301032A (en) * | 2020-11-12 | 2021-02-02 | 济南生发堂生物科技股份有限公司 | Gene inhibitor for inhibiting hair follicle stem cell aging |
CN115025216A (en) * | 2022-05-10 | 2022-09-09 | 广州乐康生物医药科技有限公司 | Compositions and methods for cancer therapy |
CN115025216B (en) * | 2022-05-10 | 2023-08-11 | 浙江颐核医疗科技有限公司 | Compositions and methods for cancer treatment |
Also Published As
Publication number | Publication date |
---|---|
CN111254146B (en) | 2021-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111254146B (en) | Application of LINC01331 gene inhibitor in preparation of medicine for treating lung cancer | |
CN107805663B (en) | Application of Lnc03729 gene as biomarker in lung adenocarcinoma pre-diagnosis reagent | |
CN111893120B (en) | Application of long-chain non-coding RNA LINC01141 in preparation of pharmaceutical composition for treating liver cancer | |
WO2021022888A1 (en) | Aso targeting long-chain non-coding rna ddx11-as1, kit and application in treatment of liver cancer | |
CN111118013B (en) | Leukemia biomarker LINC02033 and application thereof | |
CN111235275B (en) | Gene marker of lung cancer and application thereof | |
CN112795655B (en) | Colorectal cancer diagnosis marker and diagnosis kit thereof | |
CN108034655B (en) | Application of long non-coding RNA and composition thereof in diagnosis/treatment of colorectal cancer | |
CN111743912B (en) | Gene inhibitor for promoting colon cancer cell apoptosis and inhibiting colon cancer cell migration | |
CN109402253B (en) | Use of ALDH18A1 in the treatment and diagnosis of colorectal cancer | |
CN111420058B (en) | Gene inhibitor for treating prostatic cancer | |
CN108721316B (en) | Application of marker miR-652-5p in medicines and kits for metastasis, prognosis and treatment of esophageal squamous carcinoma | |
CN114522179B (en) | Application of gene preparation in preparation of colorectal cancer cell proliferation and metastasis inhibitor | |
CN107625780B (en) | Non-small cell lung cancer diagnosis marker microRNA-1253 and application thereof in medicine and diagnosis kit | |
CN111349706B (en) | Application of gene inhibitor in preparation of medicine for treating liver cancer | |
CN113549697B (en) | Gastric cancer heat chemotherapy sensitive marker and application thereof | |
CN112410429B (en) | Application of FXYD3 as gastric cancer diagnosis marker and treatment target | |
CN110577952B (en) | Application of siRNA interfering long non-coding RNA in preparation of medicine for treating breast cancer | |
CN110607368B (en) | Application of miRNA3926-1 gene as pancreatic cancer diagnosis and curative effect marker | |
CN107881237B (en) | Lung cancer diagnosis marker microRNA-4317 and application thereof in medicines and diagnosis kit | |
CN107937523B (en) | Lung cancer diagnosis marker microRNA-3607-3p and application thereof in medicines and diagnosis kit | |
CN112301030B (en) | Gene inhibitor for inhibiting Hippo signal pathway and gastric cancer | |
CN111118154B (en) | Application of LINC01272 in preparation of tumor detection reagent and/or treatment drug | |
CN109554364B (en) | TSNAX gene inhibitor and application thereof in tumors | |
CN116637123B (en) | Application of reagent for knocking down or down expression of C15orf39 gene in preparation of medicines for treating gastric cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Huang Haisen Inventor after: Zhang Jing Inventor after: Liu Yumin Inventor after: Liu Gaili Inventor after: Liu Kahua Inventor after: Yu Miaolin Inventor before: Liu Yumin Inventor before: Liu Gaili Inventor before: Liu Kahua Inventor before: Yu Miaolin |
|
CB03 | Change of inventor or designer information | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20210928 Address after: 644603 No. 1-1, floor 1, building 1, Kemao North Road, Baixi Town, Xuzhou District, Yibin City, Sichuan Province Applicant after: Sichuan novoser Biotechnology Co.,Ltd. Address before: 266042 No. 127, four Liu Nan Road, Shibei District, Qingdao, Shandong Applicant before: QINGDAO CENTRAL Hospital |
|
TA01 | Transfer of patent application right | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20211026 |
|
CF01 | Termination of patent right due to non-payment of annual fee |